News
Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
Evolva’s NootkaSHIELDTM insect repellent approved in Hong Kong
Nanobiotix: Voting Rights and Shares Capital of the Company
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website
Charles River Launches nAAVigation Vector Platform to Accelerate Gene Therapy Programs
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its nAAVigation™ Vector Platform (nAAVigation). Leveraging decades of Adeno-Associated Virus (AAV) vector
Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc
Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc
Valbiotis Accelerates Its Marketing Strategy
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Valbiotis forciert seine Marketingstrategie
Valbiotis (FR0013254851 – ALVAL, PEA / SME förderfähig), ein Unternehmen für Forschung und Entwicklung, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von Stoffwechsel-
Kapruvia® (Difelikefalin) jetzt in Deutschland für Hämodialysepatient:innen mit CKD-assoziiertem Pruritus erhältlich
CSL Vifor gab heute die Markteinführung von Kapruvia® zur Behandlung von mäßigem bis schwerem Juckreiz im Zusammenhang mit CKD bei Erwachsenen bekannt, die sich einer Hämodialyse unterziehen.1 Kapr
Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote “FOR” Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression
ICON selected by BARDA to conduct anthrax vaccine clinical trial
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces that it has been selected by the US Biomedical Advanced Research and Development
Sensorion to Present at the European Society of Gene & Cell Therapy (ESGCT) and the Gene Therapy for Rare Disorders Europe conferences in October 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening
Evolva business update: Continued good business momentum
Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Pfizer Completes Acquisition of Global Blood Therapeutics
Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced seven
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Availability of Poxel's 2022 Half-Year Financial Report
POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including
EQS-Adhoc: Heidelberg Pharma AG Announces Adjustment of Guidance
Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination
Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement for Winlevi® in Germany, Italy and Austria